PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Docket No.:2292/0HZ95 RECEIVED

> MAR 2 1 2002 TECH CENTER 1600/2900

Customer No.:

07278
PATENT TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Lechler et al.

Serial No: 09/674,462

Examiner:

Filed: May 8, 2001

Group Art Unit: 1645

Confirmation No.: 8594

Immunosuppression By Blocking T Cell Co-Stimulation Signal 2 (B7/CD28

Interaction)

SUBMISSION OF SEQUENCE LISTING AND STATEMENT PURSUANT TO 37 C.F.R. § 1.821

Hon. Commissioner of Patents and Trademarks Washington, DC 20231

Sir:

For:

Pursuant to the requirements of 37 C.F.R. §1.821 through §1.825 for Sequence Listings, a computer readable form (diskette) containing the Sequence Listing and a paper copy of the Sequence Listing is enclosed herewith.

TO Rec'd PCT/PTO T 5 MAR 2002

STATEMENT PURSUANT TO 37 C.F.R. § 1.821

Enclosed herewith is a computer readable form (diskette) containing sequence disclosure. Pursuant to Rule 37 C.F.R. §1.821, applicants herein state that the contents of the labeled diskette, specifically the ASCII-encoded file therein labeled "Seqlist.txt", is identical to the paper copy of the sequence listing submitted herewith.

Dated: March 15, 2002

Respectfully submitted,

Paul F. Fehlner, Ph.D. Registration No. 35,135

Attorney for Applicant(s)